Drug Approval | January 20, 2022
Australia grants provisional registration for Novavax Covid-19 vaccine
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
They will commercialize molnupiravir in the international markets
This is the company’s first partnership arrangement in China
The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
It provides Covid-19 detection and Omicron surveillance in less than two hours
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
Prior to IHH, Anurag held senior leadership roles in Fortis Healthcare and Manipal Health Enterprises.
Subscribe To Our Newsletter & Stay Updated
